Donor stem cell transplantation associated with survival benefit for patients with leukemia

An analysis of previous studies indicates that allogeneic stem cell transplantation (SCT) (stem cells from a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia in first complete remission, compared with nonallogeneic SCT therapies, according to an article in the June 10 issue of JAMA.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news163822596.html">Donor stem cell transplantation associated with survival benefit for patients with leukemia</a></p> <p>An analysis of previous studies indicates that allogeneic stem cell transplantation (SCT) (stem cells from a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia in first complete remission, compared with nonallogeneic SCT therapies, according to an article in the June 10 issue of <i>JAMA</i>. <br /> <br /></p>